Hong Kong’s Hang Seng Biotech Index rose 4% in early trading.

Hong Kong’s Hang Seng Biotech Index (HSBIO) rose 4% in early trading on July 2, 2026, reflecting continued investor confidence in the city’s growing biotech ecosystem. The index, which tracks the performance of leading biotech firms listed in Hong Kong, has seen significant development since the introduction of Chapter 18A in 2018, which enabled pre-revenue and R&D-focused companies to access public capital. As of April 2026, the index is composed largely of companies that have reached commercialisation, with only 5% weight to pre-revenue firms.

The biotech sector in Hong Kong has expanded beyond early-stage innovators to include late-stage drug developers and AI-enabled discovery companies. This diversification has supported the development of benchmarks, ETFs, and derivatives, enhancing liquidity and accessibility for investors. The rise of event-driven trading strategies, supported by structured products and single-stock options, has further deepened market participation.

Biotech ETFs tracking the HSBIO have also seen substantial growth, with assets under management increasing from HK$1.5 billion in March 2021 to HK$12 billion by March 2026. The launch of Hang Seng Biotech Index Futures in November 2025 has added another layer of risk management tools for investors.